Onkologie. 2025:19(2):76-79 | DOI: 10.36290/xon.2025.016

Immunotherapy in the treatment of metastatic urothelial carcinoma

Martina Spisarová, Andrea Kopová
Onkologická klinika, Fakultní nemocnice Olomouc
Lékařská fakulta Univerzity Palackého v Olomouci

Urothelial carcinoma is one of the most common cancers in its early stages. Oncologists, however, more frequently encounter patients with advanced disease. Unresec­table or metastatic urothelial carcinoma remains a significant therapeutic challenge. Traditional treatment has long relied on platinum-based chemotherapy. In recent years, this approach has evolved with the introduction of checkpoint inhibitors. A breakthrough came with combination immunotherapy regimens involving antibody-drug conjugates. The combination of pembrolizumab and enfortumab vedotin has redefined first-line treatment recommendations for urothelial carcinoma. Combination therapy is poised to become the future of urothelial carcinoma management, mirroring trends seen in the treatment of other cancers.

Keywords: immunotherapy, urothelial carcinoma, bladder cancer, immune check­point inhibitors.

Accepted: April 25, 2025; Published: May 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Spisarová M, Kopová A. Immunotherapy in the treatment of metastatic urothelial carcinoma. Onkologie. 2025;19(2):76-79. doi: 10.36290/xon.2025.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 2.5.2026

    References

    1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-183. Go to original source... Go to PubMed...
    2. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. Go to original source... Go to PubMed...
    3. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. New England Journal of Medicine. 2021;384(22):2102-2114. Go to original source... Go to PubMed...
    4. Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525-537. Go to original source... Go to PubMed...
    5. Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine. 2020;383(13):1218-1230. Go to original source... Go to PubMed...
    6. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015-1026. Go to original source... Go to PubMed...
    7. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571. Go to original source... Go to PubMed...
    8. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985;133(3):403-407. Go to original source... Go to PubMed...
    9. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483-1492. Go to original source... Go to PubMed...
    10. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. Go to original source... Go to PubMed...
    11. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438. Go to original source... Go to PubMed...
    12. Grivas P, Grande E, Davis ID, et al. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice. ESMO Open. 2023;8(6):102050. Go to original source... Go to PubMed...
    13. Powles TB, Perez Valderrama B, Gupta S, et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Annals of Oncology. 2023;34:S1340. Go to original source...
    14. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Can­cer. New England Journal of Medicine. 2024;390(10):875-888. Go to original source... Go to PubMed...
    15. Grande E, Birtle AJ, Kamat AM. Re: Thomas Powles, Begoña Pérez-Valderrama, Shilpa Gupta, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024;390:875-888. Eur Urol. 2024;86(6):e152-e153. Go to original source... Go to PubMed...
    16. van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-1789. Go to original source... Go to PubMed...
    17. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312-322. Go to original source... Go to PubMed...
    18. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-757. Go to original source... Go to PubMed...
    19. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treat­ment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. Go to original source... Go to PubMed...
    20. Alhalabi O, Campbell M, Shah A, et al. Emerging treat­ments in advanced urothelial cancer. Curr Opin Oncol. 2020;32(3):232-239. Go to original source... Go to PubMed...
    21. Kawashima A, Ishizuya Y, Yamamoto Y, et al. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution. Int J Clin Oncol. 2024;29(8):1096-1104. Go to original source... Go to PubMed...
    22. Ascione CM, Napolitano F, Esposito D, et al. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev. 2023;115:102530. Go to original source... Go to PubMed...
    23. Albarrán V, Rosero DI, Chamorro J, et al. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. Int J Mol Sci. 2022;23(20). Go to original source... Go to PubMed...
    24. Grivas P, Pouessel D, Park CH, et al. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024;42(12):1415-1425. Go to original source... Go to PubMed...
    25. Hoffman-Censits J, Grivas P, Powles T, et al. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 2024;20(4):179-190. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.